Apimeds Pharmaceuticals US, Inc.
- Last sale
- Nov 12, 2026 · -1.32%
- Market cap
- $4.16M
- 1.85M shares
- Filings
- 131
Q3 2026
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derived
—Q3 2026N/M FY25 yoy
Q3 2026+4,085.3% FY25 yoy
- $4.16M
- —
- —
- 0.0×
- -216.09%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Apimeds Pharmaceuticals US, Inc. is the 459th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
AZTRAzitra, Inc.$0.0100.0%—$4.5MBIXTBioxytran, Inc———$4.3MXBIOXenetic Biosciences, Inc.$3.0M19.0%90.1%$4.3MTRAWTraws Pharma, Inc.$2.8M1,134.5%328.7%$4.2MEMMAEmmaus Life Sciences, Inc.$12.5M25.2%60.2%$4.2MIMNNImunon, Inc.———$4.2M
APUSApimeds Pharmaceuticals US, Inc. (this company)———$4.2M
GRIGRI Bio, Inc.———$4.0MLIFDLFTD Partners Inc.$36.9M1.1%67.3%$3.7MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Apimeds Pharmaceuticals US, Inc. · CIK 1894525 · Engraved from SEC EDGAR